Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

Inclusion Criteria: * Male or female, 18 to 75 years of age * Written informed consent * No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment * Diagnosis of HBeAg negative or positive chronic HBV infection. * Must be HBsAg (+) during screening. * Must be treatment naïve: never on PEG IFN alpha 2a and/or ETV or TDF; and * Have not used nucleoside/nucleotide analogs (NUCs) within the last 2 years prior to dosing on Day 1 * Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive) (both male and female partners) Exclusion Criteria: * Pregnant or lactating * Acute signs of hepatitis/other severe infections within 4 weeks of screening * Use within the last 14 days or anticipated requirement for anticoagulants, systemic corticosteroids, immunomodulators, or immunosuppressants * Use of prescription medication within 14 days prior to treatment administration except: topical products without systemic absorption, statins (except rosuvastatin), hypertension medications, over-the-counter (OTC) and prescription pain medication or hormonal contraceptives * History of poorly controlled autoimmune disease or any history of autoimmune hepatitis * History of heterozygous or homozygous familial hypercholesterolemia. * Human immunodeficiency virus (HIV) infection * Is sero-positive for Hepatitis C Virus (HCV), or has a history of delta virus hepatitis (except for cohort in which del…